Hung Khong is an Oncology physician affiliated with Banner MD Anderson Cancer Center. OpenAlex indexes 105 publications with 4,983 citations (h-index 28); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2946 E Banner Gateway Dr
Gilbert, AZ 85234
Telephone
480-256-6444Provider last certified this registry record 30 Jun 2023.
Clinical trials
- Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eli Lilly and CompanyProgram year20252 payments
- PFIZER INC.Program year20253 payments
- Lilly USA, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68.6%Aromatase Inhibitor53.4%Anastrozole78%Letrozole22%Part D≥66 patientsKinase inhibitor7%Ibrance100%Part D<11 patients+ 2 more classes in this area
Nervous system
15.4%Phenothiazine6%Prochlorperazine Maleate100%Part D≥16 patientsGabapentinoids3.5%Gabapentin100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
11.7%Serotonin-3 Receptor Antagonist7.3%Ondansetron Hcl59%Ondansetron Odt41%Part D<11 patientsPotassium supplement4.3%Potassium Chloride100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Ralf Metzger
Banner MD Anderson Cancer Center
Isaac Bowman, MD
Banner MD Anderson Cancer Center
Fade Mahmoud, MD
Banner MD Anderson Cancer Center
Matthew Ulrickson, MD
Banner MD Anderson Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”